Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT04574635 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2025-10-27

No results posted yet for this study

Summary

This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the body (metastatic) and are undergoing treatment with surgery, radiotherapy, chemotherapy, and/or immunotherapy. Researchers may use this information to predict response (good or bad) of the cervical cancer to treatment and detect recurrent cancer sooner.

Conditions

  • Cervical Adenosquamous Carcinoma
  • Cervical Squamous Cell Carcinoma, Not Otherwise Specified
  • Infiltrating Cervical Carcinoma
  • Metastatic Cervical Carcinoma
  • Recurrent Cervical Carcinoma
  • Stage I Cervical Cancer FIGO 2018
  • Stage IA Cervical Cancer FIGO 2018
  • Stage IA1 Cervical Cancer FIGO 2018
  • Stage IA2 Cervical Cancer FIGO 2018
  • Stage IB Cervical Cancer FIGO 2018
  • Stage IB1 Cervical Cancer AJCC v8
  • Stage IB2 Cervical Cancer FIGO 2018
  • Stage IB3 Cervical Cancer FIGO 2018
  • Stage II Cervical Cancer FIGO 2018
  • Stage IIA Cervical Cancer FIGO 2018
  • Stage IIA1 Cervical Cancer FIGO 2018
  • Stage IIA2 Cervical Cancer FIGO 2018
  • Stage IIB Cervical Cancer FIGO 2018
  • Stage III Cervical Cancer FIGO 2018
  • Stage IIIA Cervical Cancer FIGO 2018
  • Stage IIIB Cervical Cancer FIGO 2018
  • Stage IIIC Cervical Cancer FIGO 2018
  • Stage IIIC1 Cervical Cancer FIGO 2018
  • Stage IIIC2 Cervical Cancer FIGO 2018
  • Stage IV Cervical Cancer FIGO 2018
  • Stage IVA Cervical Cancer FIGO 2018
  • Stage IVB Cervical Cancer FIGO 2018

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

Sponsors & Collaborators

Principal Investigators

  • Allison E. Garda, MD · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2025-09-10
Completion
2027-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04574635 on ClinicalTrials.gov